Six Companies Settle FTC CBD Marketing Regulation Violations

FTC CBD marketing
Print Friendly, PDF & Email

On December 17, 2020, the Federal Trade Commission (“FTC”) announced that it had concluded its first enforcement action against six cannabidiol (“CBD”) companies (the “Sellers”), stemming from allegations that the Sellers had deceptively advertised their CBD-based products. The FTC alleged that the Sellers made a wide range of claims, including that their CBD products could treat serious health conditions, such as cancer, heart disease, hypertension, and Alzheimer’s disease, without providing any clinical support that they could do so. As a result of their FTC CBD marketing settlement, the Sellers are prohibited from making future deceptive advertising claims, are required to provide scientific evidence to support any health claims, and, for some of them, pay a substantial fine. Businesses that sell CBD products must be aware of FTC CBD marketing regulations when advertising, or risk FTC investigation. 

What are FTC CBD Marketing Regulations?

CBD Legalization

In 2014, President Obama signed into law the 2014 Farm Bill that defined hemp, which includes CBD, as any part of the Cannabis sativa L. plant that contains no more that 0.3% of Tetrahydrocannabinol (“THC”), on a dry weight basis. In 2018, Congress signed into law the Agriculture Improvement Act of 2018 (the “Farm Bill”), which removed hemp from the Controlled Substances Act’s (“CSA”) list of illegal drugs. Following passage of the two bills, CBD companies were enthusiastic that sales of their CBD products would soon increase exponentially. CBD sales have boomed since then; however, these federal laws did not give CBD companies carte blanche to sell and advertise their CBD products without restriction. There are various state and federal regulations that must be considered in the advertisement and sale of CBD products, including regulations enforced by the FTC.

FTC CBD Marketing Regulations

The FTC prohibits unfair and deceptive advertising under Sections 5(a) and 12 of the FTC Act. “Specifically, it is unlawful to advertise that a product can prevent, treat, or cure human disease unless the advertiser possesses competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies substantiating that the claims are true at the time they are made.” Unfair or deceptive advertising includes express or implied statements made by third party endorsers. 

In the cases at hand, the Sellers made claims, without supporting scientific evidence, that CBD oil is “medically proven,” able to treat pain better than prescription medications (such as OxyContin), and that the U.S. government has confirmed certain health benefits associated with use of CBD. FTC CBD marketing regulations are meant to protect public health and enhance competitiveness in the industry. Making unsubstantiated claims about the efficacy of CBD products will likely end in an FTC investigation. This is not a favorable outcome as many FTC investigations lead to reputational harm and imposition of large monetary fines. 

To avoid an FTC investigation, businesses should consult with a knowledgeable advertising attorney early in the planning stages of any CBD marketing campaign. 

If you are the subject of an FTC investigation or need assistance with a CBD product marketing campaign, please email us at, or call us at (212) 246-0900. 

The material contained herein is provided for informational purposes only and is not legal advice, nor is it a substitute for obtaining legal advice from an attorney. Each situation is unique, and you should not act or rely on any information contained herein without seeking the advice of an experienced attorney. 

Attorney Advertising

Related Blog Posts:

Social Media Influencers and FTC Lawsuits

CBD Cosmetics Advertising Guidelines

USPTO Provides Clarity on CBD Trademark Applications

David O. Klein

David O. Klein

David Klein is one of the most recognized attorneys in the telemarketing, technology, Internet marketing, sweepstakes and telecommunications fields. Skilled at counseling clients on a broad range of technology-related matters, David Klein has substantial experience in negotiating and drafting complex licensing, marketing and Internet agreements.

Schedule a Call
In The Know

Trending Topics

New York Sweepstakes Law blog- Klein Moynihan Turco

New York Sweepstakes Law: Are You Compliant?

Print Friendly, PDF & Email

In general, a lottery exists when entrants pay for the chance to win a prize. States alone reserve the right to administer lotteries. Businesses can eliminate one element of what would otherwise be an illegal lottery, in order to transform it into a legal promotional game. If the requirement to

TCPA surveys

An Ad or not an Ad: NY Weighs in on TCPA Surveys

Print Friendly, PDF & Email

Another day, another court decision that refines constitutes a Telephone Consumer Protection Act (“TCPA”) unsolicited fax advertisement. A Manhattan-based federal court recently issued a decision that removes faxed invitations to participate in a survey from the TCPA definition of advertisement. In drawing this distinction for TCPA surveys, the Court held

NY sports gambling law- Klein Moynihan Turco

Agreement Reached to Enact NY Sports Gambling Law

Print Friendly, PDF & Email

This week, Governor Andrew Cuomo and the New York State Legislature agreed to a budget deal that will bring mobile sports betting to the State through a unique NY sports gambling law.  Upon the Governor’s signature, NY sports gambling is primed to become the nation’s largest market. However, New York

UK and US Social Media Influencer Laws

UK and US Social Media Influencer Laws

Print Friendly, PDF & Email

In September of 2020, the United Kingdom’s (“UK”) Committee of Advertising Practice (“CAP”) reviewed the Instagram accounts of 122 UK-based social media influencers to determine whether content was being properly flagged as advertising in accordance with applicable social media influencer laws. This past March, the UK Advertising Standards Authority (“ASA”)

Share on facebook
Share on google
Share on twitter
Share on linkedin